# Cipla (NSE: CIPLA) share price, financials and shareholding Source: https://app.pivotnow.in/stock/CIPLA · Pivot · prices to 21 Oct 2026 Cipla (NSE: CIPLA) closed at ₹1,316.30 on 21 Oct 2026. With a market capitalisation of ₹1,06,959 Cr, it ranks 97th by market cap among the 4,183 NSE companies Pivot tracks (a large-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic. At its last close the stock traded at 27.5× trailing earnings, against a return on equity of 11.3% in FY26. Over the past year the share price has fallen 15.6%. Its 52-week range is ₹1,165.70 (2 Apr 2026) to ₹1,673.00 (23 Oct 2025); the last close is 21.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹7,077 Cr (+3.5% year on year) and net profit ₹787 Cr (−39.1%), on a consolidated basis. Promoters held 29.21% of the company as of 30 Jun 2026. ## Key numbers | Metric | Value | | --- | --- | | Last close | ₹1,316.30 | | Market cap | ₹1,06,959 Cr | | P/E (trailing) | 27.5 | | ROE | 11.3% (FY26) | | ROCE | 15.7% (FY26) | | Debt to equity | 0.01 | | 52-week high | ₹1,673.00 (23 Oct 2025) | | 52-week low | ₹1,165.70 (2 Apr 2026) | | 1-year return | −15.6% | ## Quarterly results (₹ crore, consolidated) | Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) | | --- | --- | --- | --- | --- | --- | | Q1 FY27 | ₹7,077 Cr | +3.5% | ₹787 Cr | −39.1% | ₹9.77 | | Q4 FY26 | ₹6,464 Cr | −2.0% | ₹550 Cr | −55.1% | ₹6.87 | | Q3 FY26 | ₹6,963 Cr | −3.7% | ₹675 Cr | −57.4% | ₹8.37 | | Q2 FY26 | ₹7,447 Cr | +7.0% | ₹1,353 Cr | +3.6% | ₹16.73 | | Q1 FY26 | ₹6,837 Cr | +3.2% | ₹1,292 Cr | +9.8% | ₹16.07 | | Q4 FY25 | ₹6,598 Cr | +8.5% | ₹1,225 Cr | +31.1% | ₹15.13 | | Q3 FY25 | ₹7,232 Cr | +9.5% | ₹1,584 Cr | +48.2% | ₹19.61 | | Q2 FY25 | ₹6,961 Cr | +5.6% | ₹1,306 Cr | +13.0% | ₹16.13 | ## Annual results (₹ crore) | Fiscal year | Revenue | Net profit | | --- | --- | --- | | FY25 | ₹27,548 Cr | ₹5,291 Cr | | FY24 | ₹25,774 Cr | ₹4,155 Cr | | FY23 | ₹22,753 Cr | ₹2,835 Cr | | FY22 | ₹21,763 Cr | ₹2,559 Cr | | FY21 | ₹19,160 Cr | ₹2,401 Cr | | FY20 | ₹17,132 Cr | ₹1,547 Cr | ## Shareholding (30 Jun 2026) - Promoters: 29.21% - Foreign institutions: 20.21% - Domestic institutions: 34.63% - Non-institutions: 15.94% ## Peers | Company | Price | Market cap | P/E | ROE | | --- | --- | --- | --- | --- | | [Laurus Labs](https://app.pivotnow.in/stock/LAURUSLABS) | ₹2,061.90 | ₹1,11,394 Cr | 124.8 | 8.0% | | [Zydus Lifesciences](https://app.pivotnow.in/stock/ZYDUSLIFE) | ₹1,111.50 | ₹1,10,873 Cr | 22.2 | 18.6% | | [Apollo Hospitals Enterprise](https://app.pivotnow.in/stock/APOLLOHOSP) | ₹7,695.00 | ₹1,10,642 Cr | 57 | 20.5% | | [Dr. Reddy's Laboratories](https://app.pivotnow.in/stock/DRREDDY) | ₹1,241.20 | ₹1,03,600 Cr | 25 | 11.1% | | [Aurobindo Pharma](https://app.pivotnow.in/stock/AUROPHARMA) | ₹1,617.00 | ₹93,039 Cr | 26.8 | 9.2% | | [Mankind Pharma](https://app.pivotnow.in/stock/MANKIND) | ₹2,251.00 | ₹92,965 Cr | 48.7 | 11.7% | ## Questions and answers ### What is the share price of Cipla today? Cipla (NSE: CIPLA) last closed at ₹1,316.30 on 21 Oct 2026. Its 52-week high is ₹1,673.00 and its 52-week low is ₹1,165.70. ### What is the market cap of Cipla? Cipla's market capitalisation is ₹1,06,959 Cr (₹1.07 lakh Cr) at the 19 Oct 2026 close, ranking 97th among the NSE companies Pivot tracks. ### What is the P/E ratio of Cipla? Cipla trades at a trailing P/E of 27.5. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 48.7. ### What is the ROE and ROCE of Cipla? Return on equity was 11.3% in FY26 and return on capital employed was 15.7% in FY26 (consolidated figures). ### Is Cipla a debt-free company? Cipla is close to debt-free: its debt-to-equity ratio was 0.01 in FY26. ### What were Cipla's latest quarterly results? For Q1 FY27 (quarter ended 30 Jun 2026), Cipla reported revenue of ₹7,077 Cr, +3.5% year on year, and net profit of ₹787 Cr, −39.1% year on year. ### How has Cipla stock performed over the last year? Cipla's share price has fallen 15.6% over the past year, −7.8% over three months and −4.4% over one month, to the 19 Oct 2026 close. ### What is the shareholding pattern of Cipla? As of 30 Jun 2026: promoters 29.21%, foreign institutions 20.21%, domestic institutions 34.63%, non-institutions 15.94%. ### Who are Cipla's competitors? The listed Pharma & Healthcare companies closest to Cipla by market cap are Laurus Labs, Zydus Lifesciences, Apollo Hospitals Enterprise, Dr. Reddy's Laboratories, Aurobindo Pharma and Mankind Pharma. ### Is Cipla a good stock to buy? Pivot does not give buy or sell recommendations. This page sets out Cipla's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CIPLA against its own history before risking money. This is analysis, not financial advice. --- Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.